The detection of differentially expressed micrornas from the serum of ovarian cancer patients using a novel real-time PCR platform
|
|
- Ariel Gardner
- 6 years ago
- Views:
Transcription
1 Available online at Gynecologic Oncology 112 (2009) The detection of differentially expressed micrornas from the serum of ovarian cancer patients using a novel real-time PCR platform Kimberly E. Resnick a, Hansjuerg Alder b, John P. Hagan b, Debra L. Richardson a, Carlo M. Croce b, David E. Cohn a, a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA b Department of Molecular Biology, Virology, Immunology and Medical Genetics, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA Received 3 August 2008 Available online 26 October 2008 Abstract Objective. To determine the utility of serum mirnas as biomarkers for epithelial ovarian cancer. Methods. Twenty-eight patients with histologically confirmed epithelial ovarian cancer were identified from a tissue and serum bank. Serum was collected prior to definitive therapy. Fifteen unmatched, healthy controls were used for comparison. Serum was obtained from all patients. RNA was extracted using a derivation of the single step Trizol method. The RNA from 9 cancer specimens was compared to 4 normal specimens with real-time PCR using the TaqMan Array Human MicroRNA panel. Twenty-one mirnas were differentially expressed between normal and patient serum. Real-time PCR for the 21 individual mirnas was performed on the remaining 19 cancer specimens and 11 normal specimens. Results. Eight mirnas of the original twenty-one were identified that were significantly differentially expressed between cancer and normal specimens using the comparative C t method. MiRNAs-21, 92, 93, 126 and 29a were significantly over-expressed in the serum from cancer patients compared to controls (pb.01). MiRNAs-155, 127 and 99b were significantly under-expressed (pb.01). Additionally, mirs-21, 92 and 93 were over-expressed in 3 patients with normal pre-operative CA-125. Conclusion. We demonstrate that the extraction of RNA and subsequent identification of mirnas from the serum of individuals diagnosed with ovarian cancer is feasible. Real-time PCR-based microarray is a novel and practical means to performing high-throughput investigation of serum RNA samples. mirnas-21, 92 and 93 are known oncogenes with therapeutic and biomarker potential Elsevier Inc. All rights reserved. Keywords: Ovarian cancer; MicroRNA; Biomarkers Introduction In 2008, it is expected that 20,180 women will be diagnosed with ovarian cancer and 15,310 will succumb to the disease [1]. Ovarian cancer is a devastating illness in which only 20% of patients are diagnosed with stage I disease [2]. The poor prognosis associated with ovarian cancer is multi-factorial; a lack of minimally invasive, early detection tests, subtle symptom development and tumor chemo-resistance. Even Corresponding author. M-210 Starling Loving Hall 320 W 10th Avenue, The Ohio State University College of Medicine Columbus, OH 43210, USA. Fax: address: david.cohn@osumc.edu (D.E. Cohn). with the advent of chemo-resistance assays it is still difficult to predict drug resistance and only 10 15% of patients will remain in prolonged remission after initial cytotoxic therapy. While annual pelvic examination is widely practiced, it lacks the sensitivity to be used a screening strategy for ovarian cancer [3]. Women at high risk for ovarian cancer may typically undergo screening with trans-vaginal ultrasound and serum CA CA-125, however, remains a poor marker for early stage disease with a documented sensitivity of 40% [4,5]. Additionally, it has been shown that even in a high-risk, screened population, incident cases are still more likely to be advanced stage [6]. The identification of biomarkers that may assist in treatment planning and prediction of chemotherapy outcomes is highly desirable in this population of patients /$ - see front matter 2008 Elsevier Inc. All rights reserved. doi: /j.ygyno
2 56 K.E. Resnick et al. / Gynecologic Oncology 112 (2009) There is emerging research about the role of micrornas in a variety of pathologic conditions; including both solid and hematologic malignancies. MicroRNAs (mirnas) are small, nucleotide non-coding sequences of RNA. These sequences control gene expression either by translational repression or degradation of the messenger RNA transcript after targeting the 3 UTR. Early studies with Caenorhabditis elegans showed that a great number of these sequences are highly conserved across all species, demonstrating the important roles that mirnas play in cellular differentiation, proliferation and cell cycle control [7]. It is now recognized that mirnas are frequently de-regulated in malignancy. Under-expressed mir- NAs such as let-7 in lung cancer and mirs-15/16 in leukemia, are tumor suppressor genes, suppressing Ras and BCL2 respectively [8,9]. Over-expressed mirnas such as mir-21 and the cluster mir-17 92, are oncogenes (oncomirs), targeting tumor suppressors PTEN and E2F1 in solid and hematologic malignancies respectively [10,11]. While mirna research in gynecologic malignancies is in its infancy, the mirna signature profile of ovarian cancer has recently been published [12 14]. The diagnostic and prognostic utility of circulating RNAs in both benign and malignant conditions has recently been revealed. Placental-associated circulating mirnas correlate with pregnancy progression [15]. In malignant states, circulating mrnas in renal cell carcinoma patients [16] as well as mirnas from the serum of patients with diffuse large B cell lymphoma [17] have been shown to be stable and highly predictive of malignancy as well as survival. Recently, it has been demonstrated that the mirna signature of circulating tumor exosomes of ovarian cancer patients demonstrates high correlation with mirna expression of the primary tumor [18]. Ovarian cancer remains a disease for which improved noninvasive, serum screening tests are highly desirable. We offer a description of mirna extraction from the serum of ovarian cancer patients, the differential expression of a number of these mirnas between patients and healthy controls as well as a novel real-time PCR microarray detection method. Methods Following approval from the Institutional Review Board of The Ohio State University College of Medicine we analyzed serum samples from 28 patients with newly diagnosed ovarian cancer and 15 normal controls. These serum samples were collected at the time of initial consultation, prior to definitive surgical management and/or adjuvant therapy. The serum was obtained as part of a prospective tissue and serum procurement study and was stored at 80 C. Fresh serum was obtained from 15 healthy women who volunteered to serve as controls. The frozen serum was thawed and RNA was extracted from the patient and control populations simultaneously. None of the healthy controls had previously been diagnosed with a malignancy. RNA was extracted from 250 μl of serum using the Tri- Reagent BD (Molecular Research Center, Inc., Cincinnati, OH) as described by the manufacturer. RNA quality was assessed with the ThermoScientific NanoDrop1000 (Thermo Fisher Scientific, Inc., Waltham, MA). MicroRNA expression profiling was performed with RNA from 4 controls and 9 cancer patients utilizing the TaqMan Array Human MicroRNA Panel (v.1, Applied Biosystems, Foster City, CA) using 50 ng of RNA per port for a total of 400 ng. This array contains 365 mirna targets as well as endogenous controls. Normalization was performed with the small nuclear RNAs (snrnas) U44 and U48. These snrnas are stably expressed reference genes suitable for use as normalizers in TaqMan assays. In addition to identifying differentially expressed mirnas on the microarray panel, a second goal was to identify mirnas that may serve as normalizers given the lack of published data on the subject. Twenty-one mirnas from the expression profile were empirically chosen for further examination in control and patient serum (11 controls and 19 patients). These were chosen based on apparent C t differences of 4 cycles or greater between controls and patients. Two mirnas (142-3p and 16) were identified as potential normalizers given consistent expression across all patient and control samples. For the mirnas of interest the single tube TaqMan MicroRNA Assays were used. All reagents, primers and probes were obtained from Applied Biosystems (Applied Biosystems, Foster City, CA). One nanogram of RNA per sample was used for the assays. MiRNA-142-3p was used as a normalizer. All RT reactions, including no-template (no cdna) controls and minus controls (no reverse transcriptase), were run in a GeneAmp PCR 9700 Thermocycler (Applied Biosystems). Gene expression levels were quantified using the ABI Prism 7900HT Sequence detection system (Applied Biosystems). Comparative realtime PCR was performed in triplicate, including no-template controls. Expression of the micrornas was calculated utilizing the comparative C t. method. Statistical analysis was performed with STATA v. 10 (College Station, TX). Expression was compared using the Mann Whitney test. P-values b 0.05 were considered statistically significant. Results Twenty-eight patients with epithelial ovarian cancer were included in this study. Stage breakdown was as follows: stage I- 8 (28.5%), stage II-2 (7.1%), stage III-8 (28.5%) stage IV-10 (35.7%). Histologic breakdown was as follows: serous (60%), clear cell (21.2%), endometrioid (12%), mucinous (6%). Median age was 57 years (age range 34 79). Similar to most groups with ovarian cancer, the majority (66%) had stage III or IV disease, and was predominately (60%) serous histology. Primary mirna expression profiling with microarray identified 23 mirnas (including 2 normalizers) of interest. We created a Venn diagram in order to compare our 23 mirnas of interest from our initial test set with known mirna signature profiles. There were 10 mirnas of interest in our group that were in common with mirnas that have been published in the literature as part of the mirna signatures of ovarian cancer (Fig. 1). On follow up quantitative RT-PCR of the 21 mirnas, 5 mirnas were over-expressed (mirnas-21, 29a, 92, 93 and
3 K.E. Resnick et al. / Gynecologic Oncology 112 (2009) Fig. 1. Comparison of published mirna profile and differentially expressed mirnas from ovarian cancer patient serum. 126, p=.0002, p=.003, p=.0001, p =.0003, p=.007) and 3 mirnas were under-expressed (mir-127, 155 and 99b, p=.0001, p=.0003, p=.0001) in the serum of ovarian cancer patients compared to controls. Fold-differences in median expression of the mirnas in patients versus controls are demonstrated in Fig. 2. Three patients were identified with pre-operative CA- 125b35 U/ml. We then examined the three mirnas with the highest serum expression, mirs-21, 92 and 93 for expression patterns in those patients with normal CA-125 in order to determine if mirna patterns mimicked CA-125 patterns. These three mirnas were found to be significantly over-expressed in Fig. 2. Median fold-change differences in differentially expressed mirnas between patient and control serum. these patients when median expression in the patient population was compared to controls (Table 1). There was no correlation between mirna status and grade, stage or histologic subtype. Due to the small sample size and recent diagnosis of disease we did not attempt to correlate mirna status with progression-free interval or survival. Discussion We demonstrate that the extraction of RNA and identification of mirnas from the serum of individuals diagnosed with ovarian cancer is feasible. We offer the first description of using a real-time PCR, microarray platform to screen large numbers of mirnas while minimizing the amount of RNA needed. Additionally, we provide evidence that mirnas may potentially serve as early detection biomarkers in patients with normal CA-125. With our approach we were able to create a profile that was subsequently examined on a set of 19 patients and 11 healthy controls. Out of the 21 mirnas of interest that we selected, 10 mirnas were common to published ovarian cancer profiles. Among the 5 over-expressed mirnas that we discovered are three potential oncomirs; mirs-21, 92 and 93. Over-expression of mir-21 has been demonstrated in glioblastoma, breast, colon, prostate, lung, pancreas and stomach cancers [19,20]. It has been shown to modulate expression of PTEN in hepatocellular carcinoma [10] as well as PDCD4 and maspin, two genes involved in regulating invasion and metastasis [21,22]. The most consistently over-expressed mirna in serum from patients was mir-92. Mir-92a-1 is part of the mir-17 92
4 58 K.E. Resnick et al. / Gynecologic Oncology 112 (2009) Table 1 mirna over-expression in patients with normal pre-operative CA-125 ID FIGO Stage CA-125 (u/ml) mir-21 Patient a /Control b mir-92 Patient/Control c mir-93 Patient/Control d IIC / / / IV / /4.3 14/ IA / / /.76 a Individual patient serum mirna expression is defined as the 2(ΔCt). b Inter-quartile range for median expression of mir-21 in controls: (.68.93). c Inter-quartile range for median expression of mir-92 in controls: ( ). d Inter-quartile range for median expression of mir-93 in controls: ( ). polycistron, located on chromosome 13q13. A known oncomir, mir enforced expression in a transgenic mouse model of lymphoma unequivocally demonstrated accelerated lymphoma progression [23]. Over-expression of mir-93 was associated with decreased progression-free and overall survival in ovarian cancer patients [13]. In gastric tumors, this cluster negatively regulated TGFβ tumor suppressor activities [24]. The proposed oncogenic activities of both mir-92 and mir-93 agree with our serum findings. Contrary to the published ovarian cancer profiles, we have demonstrated significant over-expression of mir-29a and mir-126 in the sera from ovarian cancer patients. There have been a number of tumor suppressor activities proposed for both mir-126 and 29a. Mir-126 has been implicated as a metastatic-suppressor in breast cancer with loss associated with poor outcome [25]. Mir-29a has been found to be under-expressed in lung cancers; having been implicated in the modulation of methylation patterns seen in lung cancer [26]. While over expression of these mirnas would tend to suggest they behave as oncomirs, TargetScan (4.2) does predict PTEN as a potential target of mir-29a. Whether or not these mirnas exhibit predominant tumor suppressor or oncogenic activity remains to be seen. Mir-127 has been identified as one of thirty-one downregulated mirnas in ovarian cancer cell lines [14]. It has recently been shown to be embedded in a CpG island and silenced completely in most cancer cell lines. In this same study, it was demonstrated that treatment of cell lines with 5-aza-2 - deoxycytidine not only restored mir-127 expression but also reduced expression of the proto-oncogene BCL6 [27]. Taken together these results identify mir-127 as a putative tumor suppressor gene, supporting our findings of decreased expression in patient serum. Our study is hindered by the limited amount of published data regarding the extraction of quality mirna from serum. While we did experience RNA degradation as well as genomic DNA contamination (results not shown), only 400 ng of total RNA are required for the TaqMan Array Human MicroRNA. Additionally, given that the amplicons of interest are approximately nucleotides, we feel that some degradation of the RNA is tolerable. More importantly, the controls used in real-time PCR should account for both cross contamination by reagents (notemplate control) as well as genomic DNA contamination (RT minus control). As microarray chips typically utilize up to 5 μg of sample, we feel that our real-time based approach will be superior until methods for extracting large amounts of pure RNA from serum are established. To our knowledge, this is the first description of utilizing this technology to obtain a mirna profile on serum RNA. Our sample size is small and lacks long-term outcome data. Additionally, it remains unclear whether these serum mirnas are necessarily tumor-derived, associated with cellular contaminant or mirnas involved in the host immune and/or stress response. While a number of mirnas in our test set are important modulators of the immune response [28] the recent report by Taylor et al. [18] certainly provides proof of principle that serum-derived mirna is a function of the mirna signature at the tumor level. We present a pilot study demonstrating the potential utility of mirnas as either biomarkers for further prospective evaluation in ovarian cancer detection studies or therapeutic targets. Conflict of interest statement The authors have no conflicts of interest to declare. Acknowledgment This work was supported by the Jacquelyn L. Wells Endowment in Ovarian Cancer Research to D.E.C. and The Ohio State University Targets and Investments in Excellence Award to C.C. References [1] Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58(2): [2] Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351(24): [3] Myers ER, Bastian LA, Havrilesky LJ, et al. Management of adnexal masses. Evid Rep/ Technol Assess 2006(130): [4] Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3(4): [5] Jacobs I, Davies AP, Bridge J, et al. Prevalence screening for ovarian cancer in post-menopausal women by CA-125 measurement and ultrasonography. BMJ 1993;306: [6] Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100(1):20 6. [7] Jannot G, Simard MJ. Tumor-related micrornas functions in Caenorhabditis elegans. Oncogene 2006;25(46): [8] Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microrna family. Cell 2005;120(5): [9] Cimmino A, Calin GA, Fabbri M, et al. mir-15 and mir-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102(39): [10] Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133(2): [11] Mendell JT. miriad roles for the mir cluster in development and disease. Cell 2008;133(2):
5 K.E. Resnick et al. / Gynecologic Oncology 112 (2009) [12] Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67(18): [13] Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14(9): [14] Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microrna expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008;105(19): [15] Chim SS, Shing TK, Hung EC, et al. Detection and characterization of placental micrornas in maternal plasma. Clin Chem 2008;54(3): [16] Feng G, Li G, Gentil-Perret A, Tostain J, Genin C. Elevated serumcirculating RNA in patients with conventional renal cell cancer. Anticancer Res 2008;28(1A): [17] Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumourassociated micrornas in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141(5): [18] Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110(1): [19] Volinia S, Calin GA, Liu CG, et al. A microrna expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103(7): [20] Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an anti apoptotic factor in human glioblastoma cells. Cancer Res 2005;65: [21] Zhu S, Wu H, Wu F, et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008;18(3): [22] Secord AA, Lee PS, Darcy KM, et al, Gynecologic Oncology Group. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a gynecologic oncology group study. Gynecol Oncol 2006;101 (3): [23] He L, Thomson JM, Hemann MT, et al. A microrna polycistron as a potential human oncogene. Nature 2005;435(7043): [24] Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated micrornas impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008;13(3): [25] Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human micrornas that suppress breast cancer metastasis. Nature 2008;451 (7175): [26] Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007;104(40): [27] Saito Y, Liang G, Egger G, et al. Specific activation of microrna-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9(6): [28] Tili E, Michaille JJ, Calin GA. Expression and function of micro-rnas in immune cells during normal or disease state. Int J Med Sci 2008;5(2): 73 9.
microrna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationThe clinical relevance of circulating, cell-free and exosomal micrornas as biomarkers for gynecological tumors
Department of Tumor Biology The clinical relevance of circulating, cell-free and exosomal micrornas as biomarkers for gynecological tumors cfdna Copenhagen April 6-7, 2017 Heidi Schwarzenbach, PhD Tumor
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationMir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2017; 21: 4278-4282 Mir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer Q.-H. ZHOU 1, Y.-M. ZHAO 2, L.-L.
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationMicroRNA-92gene expression in epithelial ovarian cancer using a novel Real-Time Polymerase change reaction
www.muthjm.com Muthanna Medical Journal 2016; 3(1):23-33 MicroRNA-92gene expression in epithelial ovarian cancer using a novel Real-Time Polymerase change reaction Shoroq Mohammed AL-Temimi 1* Abstract
More informationEvaluation of altered expression of mir-9 and mir-106a as an early diagnostic approach in gastric cancer
Original Article Evaluation of altered expression of mir-9 and mir-106a as an early diagnostic approach in gastric cancer Khadije Shirmohammadi, Sareh Sohrabi, Zahra Jafarzadeh Samani, Hosein Effatpanah,
More informationDownregulation of serum mir-17 and mir-106b levels in gastric cancer and benign gastric diseases
Brief Communication Downregulation of serum mir-17 and mir-106b levels in gastric cancer and benign gastric diseases Qinghai Zeng 1 *, Cuihong Jin 2 *, Wenhang Chen 2, Fang Xia 3, Qi Wang 3, Fan Fan 4,
More informationLow levels of serum mir-99a is a predictor of poor prognosis in breast cancer
Low levels of serum mir-99a is a predictor of poor prognosis in breast cancer J. Li 1, Z.J. Song 2, Y.Y. Wang 1, Y. Yin 1, Y. Liu 1 and X. Nan 1 1 Tumor Research Department, Shaanxi Provincial Tumor Hospital,
More informationMicroRNA Cancer qpcr Array
MicroRNA Cancer qpcr Array Array Layout Pre-designed set of 95 MicroRNA detection Primers U6 snrna Normalization transcript Selection of Candidate MicroRNAs for Cancer Array Sample References of MicroRNA
More informationmicrornas (mirna) and Biomarkers
micrornas (mirna) and Biomarkers Small RNAs Make Big Splash mirnas & Genome Function Biomarkers in Cancer Future Prospects Javed Khan M.D. National Cancer Institute EORTC-NCI-ASCO November 2007 The Human
More informationClinical significance of serum mir-21 in breast cancer compared with CA153 and CEA
Original Article Clinical significance of serum mir-21 in breast cancer compared with CA153 and CEA Jianjian Gao, Qingyun Zhang, Jianjun Xu, Lijuan Guo, Xuefeng Li Key Laboratory of Carcinogenesis and
More informationMicroRNAs: the primary cause or a determinant of progression in leukemia?
MicroRNAs: the primary cause or a determinant of progression in leukemia? The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationExpression and significance of mir-21 in multiple myeloma patients
Expression and significance of mir-21 in multiple myeloma patients J.H. Wang 1, W.W. Zhou 1, B.X. Liu 1, D.L. Man 1, Z.D. Yang 1, F.R. Liu 2 and H. Shang 1 1 The Laboratory Medicine of First Affiliated
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationThe diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer
European Review for Medical and Pharmacological Sciences 2017; 21: 4039-4044 The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer H.-Y. FAN
More informationThe Diagnostic and Prognostic Role of Serum MicroRNAs in Ovarian Cancer
The Diagnostic and Prognostic Role of Serum MicroRNAs in Ovarian Cancer Yin Min (First author) Medical College of Qingdao University, Qingdao, Shandong Province, China Chen Aiping (Corresponding author)
More informationProducts for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma
MACHEREY-NAGEL Products for cfdna and mirna isolation Bioanalysis Subhead Circulating Cover nucleic acids from plasma n Flexible solutions for small and large blood plasma volumes n Highly efficient recovery
More informationCancer Problems in Indonesia
mirna and Cancer : mirna as a Key Regulator in Cancer Sofia Mubarika 2 nd Symposium Biomolecular Update in Cancer PERABOI Padang 18 Mei 2013 Cancer Problems in Indonesia 1. Chemoresistency / recurrency
More informationOriginal Article microrna-217 was downregulated in ovarian cancer and was associated with poor prognosis
Int J Clin Exp Pathol 2016;9(8):8555-8559 www.ijcep.com /ISSN:1936-2625/IJCEP0026997 Original Article microrna-217 was downregulated in ovarian cancer and was associated with poor prognosis Qiong Pan,
More informationCircular RNA_LARP4 is lower expressed and serves as a potential biomarker of ovarian cancer prognosis
European Review for Medical and Pharmacological Sciences 2018; 22: 7178-7182 Circular RNA_LARP4 is lower expressed and serves as a potential biomarker of ovarian cancer prognosis T. ZOU, P.-L. WANG, Y.
More informationAssociation between downexpression of mir-1301 and poor prognosis in patients with glioma
European Review for Medical and Pharmacological Sciences 2017; 21: 4298-4303 Association between downexpression of mir-1301 and poor prognosis in patients with glioma Q.-L. BAI, C.-W. HU, X.-R. WANG, G.-F.
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationIDENTIFICATION OF BIOMARKERS FOR EARLY DIAGNOSIS OF BREAST CANCER"
IDENTIFICATION OF BIOMARKERS FOR EARLY DIAGNOSIS OF BREAST CANCER" Edmond Marzbani, MD December 2, 2008 Early diagnosis of cancer Many solid tumors are potentially curable if diagnosed at an early stage
More informationRALYL Hypermethylation: A Potential Diagnostic Marker of Esophageal Squamous Cell Carcinoma (ESCC) Junwei Liu, MD
RALYL Hypermethylation: A Potential Diagnostic Marker of Esophageal Squamous Cell Carcinoma (ESCC) Junwei Liu, MD Aurora Healthcare, Milwaukee, WI INTRODUCTION v Epigenetic aberration and genetic alteration
More informationNovel Biomarkers (Kallikreins) for Prognosis and Therapy Response in Ovarian cancer
Novel Biomarkers (Kallikreins) for Prognosis and Therapy Response in Ovarian cancer Eleftherios P. Diamandis, M.D., Ph.D., FRCP(C) EORTC-NCI-ASCO Meeting,November 16, 2007 Yousef GM, Diamandis EP. Endocr.
More information95% CI: , P=0.037).
Biomedical Research 2017; 28 (21): 9248-9252 Reduced expression level of mir-205 predicts poor prognosis in Qiang Yang 1*#, Peng Sun 2#, Haotian Feng 1, Xin Li 1, Jianmin Li 1 1 Department of Orthopedics,
More informationMicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease
DOI 10.4110/in.2011.11.3.135 pissn 1598-2629 eissn 2092-6685 REVIEW ARTICLE MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease * Department of Immunology, Chonbuk National University Medical
More informationMicroRNA dysregulation in cancer. Systems Plant Microbiology Hyun-Hee Lee
MicroRNA dysregulation in cancer Systems Plant Microbiology Hyun-Hee Lee Contents 1 What is MicroRNA? 2 mirna dysregulation in cancer 3 Summary What is MicroRNA? What is MicroRNA? MicroRNAs (mirnas) -
More informationDecreased expression of mir-490-3p in osteosarcoma and its clinical significance
European Review for Medical and Pharmacological Sciences Decreased expression of mir-490-3p in osteosarcoma and its clinical significance B. TANG, C. LIU, Q.-M. ZHANG, M. NI Department of Orthopedics,
More informationScreening for novel oncology biomarker panels using both DNA and protein microarrays. John Anson, PhD VP Biomarker Discovery
Screening for novel oncology biomarker panels using both DNA and protein microarrays John Anson, PhD VP Biomarker Discovery Outline of presentation Introduction to OGT and our approach to biomarker studies
More informationTable S2. Expression of PRMT7 in clinical breast carcinoma samples
Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#
More informationMicroRNA in Cancer Karen Dybkær 2013
MicroRNA in Cancer Karen Dybkær RNA Ribonucleic acid Types -Coding: messenger RNA (mrna) coding for proteins -Non-coding regulating protein formation Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationOriginal Article Increased expression of microrna-196a predicts poor prognosis in human ovarian carcinoma
Int J Clin Exp Pathol 2015;8(4):4132-4137 www.ijcep.com /ISSN:1936-2625/IJCEP0006320 Original Article Increased expression of microrna-196a predicts poor prognosis in human ovarian carcinoma Yi Fan, Jin
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationIdentification of a MicroRNA Panel for Clear-cell Kidney Cancer
Identification of a MicroRNA Panel for Clear-cell Kidney Cancer Cancer David Juan, Gabriela Alexe, Travis Antes, Huiqing Liu, Anant Madabhushi, Charles Delisi, Shridhar Ganesan, Gyan Bhanot, and Louis
More information3 Summary of clinical applications and limitations of measurements
CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin-16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant
More informationdeveloping new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success
micrornas developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success Dr. Carola Wagner IMGM Laboratories GmbH Martinsried, Germany qpcr 2009 Symposium
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationResearch Article Next-Generation Sequencing of MicroRNAs for Breast Cancer Detection
Hindawi Publishing orporation Journal of Biomedicine and Biotechnology Volume, Article ID 97, 7 pages doi:.//97 Research Article Next-Generation Sequencing of MicroRNAs for Breast ancer Detection Qian
More informationMicroRNA Signatures in Human Ovarian Cancer
Research Article MicroRNA Signatures in Human Ovarian Cancer Marilena V. Iorio, 1 Rosa Visone, 2 Gianpiero Di Leva, 2 Valentina Donati, 2 Fabio Petrocca, 2 Patrizia Casalini, 1 Cristian Taccioli, 2 Stefano
More informationThe association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis
Wang et al. Journal of Ovarian Research (2016) 9:23 DOI 10.1186/s13048-016-0231-1 RESEARCH The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis
More informationmir-125a-5p expression is associated with the age of breast cancer patients
mir-125a-5p expression is associated with the age of breast cancer patients H. He 1 *, F. Xu 2 *, W. Huang 1, S.Y. Luo 1, Y.T. Lin 1, G.H. Zhang 1, Q. Du 1 and R.H. Duan 1 1 The State Key Laboratory of
More informationRESEARCH ARTICLE. Hariyono Winarto*, Bismarck Joel Laihad, Laila Nuranna. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.5.1949 RESEARCH ARTICLE Modification of Cutoff Values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for Ovarian Cancer Detection
More informationBerberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through mir-93/ PTEN/Akt Signaling Pathway
Chen Accepted: et al.: February Berberine 24, Sensitizes 2015 Ovarian Cancer Cells to Cisplatin www.karger.com/cpb 956 1421-9778/15/0363-0956$39.50/0 Original Paper This is an Open Access article licensed
More informationReduced mirna-218 expression in pancreatic cancer patients as a predictor of poor prognosis
Reduced mirna-218 expression in pancreatic cancer patients as a predictor of poor prognosis B.-S. Li, H. Liu and W.-L. Yang Department of Gastrointestinal and Pancreatic Surgery, The Third Xiangya Hospital
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ueda T, Volinia S, Okumura H, et al.
More informationMicro RNA Research. Ken Kosik. Harriman Professor, Department of Molecular, Cellular & Developmental Biology and Biomolecular Sciences & Engr.
Ken Kosik Harriman Professor, Department of Molecular, Cellular & Developmental Biology and Biomolecular Sciences & Engr. Program Co-Director, Neurosciences Research Institute Micro RNA Research Neuroscience
More informationCircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 3713-3718 CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer N. LIU 1, J. ZHANG 1, L.-Y. ZHANG 1, L.
More informationSerum mir-200c expression level as a prognostic biomarker for gastric cancer
Serum mir-200c expression level as a prognostic biomarker for gastric cancer H.-P. Zhang 1 *, F.-B. Sun 2 * and S.-J. Li 2 1 Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Yantai,
More informationAssociation of microrna 21 With Biological Features and Prognosis of Neuroblastoma
Special Report Association of microrna 21 With Biological Features and Prognosis of Neuroblastoma Yaodong Zhou, MD, and Bo Sheng, MD Background: The aim of this study was to assess the differences in microrna
More informationMEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
More informationOverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA
OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.
More informationStudy on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value
Study on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value Shen Wei 1,a, Chen Juan 2, Li Xiurong 1 and Yin Jie 1 1 Department of Obstetrics and Gynecology,
More informationMicroRNA and Male Infertility: A Potential for Diagnosis
Review Article MicroRNA and Male Infertility: A Potential for Diagnosis * Abstract MicroRNAs (mirnas) are small non-coding single stranded RNA molecules that are physiologically produced in eukaryotic
More informationAmoyDx TM BRAF V600E Mutation Detection Kit
AmoyDx TM BRAF V600E Mutation Detection Kit Detection of V600E mutation in the BRAF oncogene Instructions For Use Instructions Version: B3.1 Date of Revision: April 2012 Store at -20±2 o C 1/5 Background
More informationHigh AU content: a signature of upregulated mirna in cardiac diseases
https://helda.helsinki.fi High AU content: a signature of upregulated mirna in cardiac diseases Gupta, Richa 2010-09-20 Gupta, R, Soni, N, Patnaik, P, Sood, I, Singh, R, Rawal, K & Rani, V 2010, ' High
More informationBecause ovarian cancer is usually diagnosed
OVARIAN CANCER Recent studies shed light on early detection of but it s not a green light for routine screening. Until promising avenues of research lead further, refer women who have an adnexal mass,
More informationExploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies
Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Disclosures MDxHealth Scientific Advisor 2 Case Study 54-year-old man referred for a PSA of 7 - Healthy, minimal
More information10/31/2017. micrornas and cancer. From the one gene-one enzyme hypothesis to. microrna DNA RNA. Transcription factors.
micrornas and cancer Cellular and Molecular Biology of Cancer (PATH G4500-001) November 1 st, 2017 -Katia Basso- Columbia University Katia Basso, PhD Office: ICRC RM506 E-mail: kb451@cumc.columbia.edu
More informationSerum mirna expression profile as a prognostic biomarker of stage II/III
Serum mirna expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma Jialu Li a,b,, Yang Liu c,, Cheng Wang d,, Ting Deng a,, Hongwei Liang b, Yifei Wang e, Dingzhi Huang
More informationMicroRNA-29a Reveals Oncogenic Role on Myeloid Malignancies by Regulating DNMT3A
MicroRNA-29a Reveals Oncogenic Role on Myeloid Malignancies by Regulating DNMT3A Heba Alkhatabi, PhD Assistant Professor Department of Medical Laboratory Collage of Applied Medical science King Abdul Aziz
More informationHigh Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.24.10621 RESEARCH ARTICLE High Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas Yao-Wu Wang 1, Chun-Li Yin 2, Hong-Yi Zhang
More informationONCOGENESIS A multistep process comprised of
by Dr JO Serrentino The seminar/webinar is for the purposes of continuing education and available to registrants only. No part of this material may be duplicated in any format without the expressed written
More informationAssociation of mir-21 with esophageal cancer prognosis: a meta-analysis
Association of mir-21 with esophageal cancer prognosis: a meta-analysis S.-W. Wen 1, Y.-F. Zhang 1, Y. Li 1, Z.-X. Liu 2, H.-L. Lv 1, Z.-H. Li 1, Y.-Z. Xu 1, Y.-G. Zhu 1 and Z.-Q. Tian 1 1 Department of
More informationMethylation status of SOCS1 and SOCS3 in BCR-ABL negative and. JAK2V617F negative chronic myeloproliferative disorders.
Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative disorders. To the Editor BCR-ABL negative Chronic Myeloproliferative Disorders (s) are a heterogeneous
More informationPlasma Bmil mrna as a potential prognostic biomarker for distant metastasis in colorectal cancer patients
Title Plasma Bmil mrna as a potential prognostic biomarker for distant metastasis in colorectal cancer patients Author(s) Pun, JC; Chan, JY; Chun, BK; Ng, KW; Tsui, SY; Wan, TMH; Lo, OSH; Poon, TCJ; Ng,
More informationa) List of KMTs targeted in the shrna screen. The official symbol, KMT designation,
Supplementary Information Supplementary Figures Supplementary Figure 1. a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation, gene ID and specifities are provided. Those highlighted
More informationExpression of Micro-RNA 128 and Let-7b in Pediatric Acute Lymphoblastic Leukemia Cases
DOI:10.22034/APJCP.2018.19.8.2263 RESEARCH ARTICLE Editorial Process: Submission:03/05/2018 Acceptance:07/17/2018 Expression of Micro-RNA 128 and Let-7b in Pediatric Acute Lymphoblastic Leukemia Cases
More informationSoft Agar Assay. For each cell pool, 100,000 cells were resuspended in 0.35% (w/v)
SUPPLEMENTARY MATERIAL AND METHODS Soft Agar Assay. For each cell pool, 100,000 cells were resuspended in 0.35% (w/v) top agar (LONZA, SeaKem LE Agarose cat.5004) and plated onto 0.5% (w/v) basal agar.
More informationIs It Time To Implement Ovarian Cancer Screening?
Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationmir-129b suppresses cell proliferation in the human lung cancer cell lines A549 and H1299
mir-129b suppresses cell proliferation in the human lung cancer cell lines A549 and H1299 L. Zheng, Y.X. Qi, S. Liu, M.L. Shi and W.P. Yang Department of Respiratory Medicine, People s Hospital of Laiwu
More informationARTICLE IN PRESS. Critical Reviews in Oncology/Hematology xxx (2010) xxx xxx
Critical Reviews in Oncology/Hematology xxx (2010) xxx xxx Circulating micrornas: Association with disease and potential use as biomarkers Glen Reid, Michaela B. Kirschner, Nico van Zandwijk Asbestos Diseases
More informationIdentification of Suitable Reference Genes for qpcr Analysis of Serum microrna in Gastric Cancer Patients
DOI 10.1007/s10620-011-1981-7 ORIGINAL ARTICLE Identification of Suitable Reference Genes for qpcr Analysis of Serum microrna in Gastric Cancer Patients Jianning Song Zhigang Bai Wei Han Jun Zhang Hua
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationRoles of microrna-mediated Drug Resistance in Tumor Stem Cells of Small Cell Lung Carcinoma
AD Award Number: W81XWH-12-1-0479 TITLE: Roles of microrna-mediated Drug Resistance in Tumor Stem Cells of Small Cell Lung Carcinoma PRINCIPAL INVESTIGATOR: Kounosuke Watabe, Ph.D. CONTRACTING ORGANIZATION:
More informationOriginal Article Up-regulation of mir-10a and down-regulation of mir-148b serve as potential prognostic biomarkers for osteosarcoma
Int J Clin Exp Pathol 2016;9(1):186-190 www.ijcep.com /ISSN:1936-2625/IJCEP0018032 Original Article Up-regulation of mir-10a and down-regulation of mir-148b serve as potential prognostic biomarkers for
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationDNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA
DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias
More informationDown-regulation of mir p is correlated with clinical progression and unfavorable prognosis in gastric cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 5914-5919 Down-regulation of mir-1236-3p is correlated with clinical progression and unfavorable prognosis in gastric cancer X.-P. ZHU
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationThe Interaction of Alcohol and Iron-Overload in the in-vivo Regulation of Iron Responsive Genes
Cantaurus, Vol. 5, -, May 7 McPherson College Division of Science and Technology The Interaction of Alcohol and Iron-Overload in the in-vivo Regulation of Iron Responsive Genes Callie Crist, Elizabeth
More informationPerfiles de expresión génica y nuevas dianas terapéuticas en cáncer de endometrio
Perfiles de expresión génica y nuevas dianas terapéuticas en cáncer de endometrio Curso Corto Actualización en Patología Ginecológica David Hardisson Departamento de Anatomía Patológica CA. DE ENDOMETRIO
More informationmir-206 Expression Is Down-regulated in Estrogen Receptor A Positive Human Breast Cancer
Priority Report mir-206 Expression Is Down-regulated in Estrogen Receptor A Positive Human Breast Cancer Naoto Kondo, Tatsuya Toyama, Hiroshi Sugiura, Yoshitaka Fujii, and Hiroko Yamashita Oncology, Immunology,
More informationClinical significance of serum mir-196a in cervical intraepithelial neoplasia and cervical cancer
Clinical significance of serum mir-196a in cervical intraepithelial neoplasia and cervical cancer P. Liu 1, F. Xin 1 and C.F. Ma 2 1 Department of Obstetrics & Gynecology, Baoding Second Central Hospital,
More informationMicroRNA-126 is Dysregulated in Cancer- Free Females Harboring Methylated BRCA1 Promoter through Up-Regulation of DNMTs
Commentary imedpub Journals http://www.imedpub.com Journal of Clinical Epigenetics ISSN 47-58 Vol.3 No. S:3 DOI:.767/47-58.37 MicroRNA-6 is Dysregulated in Cancer- Free Females Harboring Methylated BRCA
More informationIntroduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
More informationDOES THE BRCAX GENE EXIST? FUTURE OUTLOOK
CHAPTER 6 DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK Genetic research aimed at the identification of new breast cancer susceptibility genes is at an interesting crossroad. On the one hand, the existence
More informationONCOLOGY LETTERS 6: , 2013
ONCOLOGY LETTERS 6: 261-267, 2013 Identification of four serum micrornas from a genome wide serum microrna expression profile as potential non invasive biomarkers for endometrioid endometrial cancer WENHUI
More informationOriginal Article Reduced expression of mir-506 in glioma is associated with advanced tumor progression and unfavorable prognosis
Int J Clin Exp Pathol 2016;9(1):181-185 www.ijcep.com /ISSN:1936-2625/IJCEP0017823 Original Article Reduced expression of mir-506 in glioma is associated with advanced tumor progression and unfavorable
More informationMyelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression
Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.
More informationProfiles of gene expression & diagnosis/prognosis of cancer Lorena Roa de la Cruz
Genomics Profiles of gene expression & diagnosis/prognosis of cancer Lorena Roa de la Cruz Gene expression profiling Measurement of the activity of thousands of genes at once Techniques used for gene expression
More informationFrom reference genes to global mean normalization
From reference genes to global mean normalization Jo Vandesompele professor, Ghent University co-founder and CEO, Biogazelle qpcr Symposium USA November 9, 2009 Millbrae, CA outline what is normalization
More informationA novel and universal method for microrna RT-qPCR data normalization
A novel and universal method for microrna RT-qPCR data normalization Jo Vandesompele professor, Ghent University co-founder and CEO, Biogazelle 4 th International qpcr Symposium Weihenstephan, March 1,
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationmicrorna PCR System (Exiqon), following the manufacturer s instructions. In brief, 10ng of
SUPPLEMENTAL MATERIALS AND METHODS Quantitative RT-PCR Quantitative RT-PCR analysis was performed using the Universal mircury LNA TM microrna PCR System (Exiqon), following the manufacturer s instructions.
More information